Differential effect of dipyridamole upon thymidine incorporation and expression of surface activation antigens by in vitro stimulated lymphocytes.
Dipyridamole inhibits, by 50% at 10(-6) M and 100% at 10(-5) M, the incorporation of tritiated thymidine by lymphocytes stimulated with 1 microgram/ml phytohaemagglutinin A for 72 h. At the latter concentration, a clinically relevant one, dipyridamole fails to inhibit lymphocyte proliferation and expression of the cell surface stimulation markers, CD25 and HLA-DR, or differential regulation of the CD45 -RA and -RO isoforms, as determined by single laser two-colour flow-cytometry. No significant immunodepressant effect of dipyridamole can be demonstrated in vitro.
Higuet
N
N
Laboratoire de Médecine Expérimentale (Université Libre de Bruxelles), C.H.U. André Vésale, Montigny-le-Tilleul, Belgium.
Brohée
D
D
D000328:Adult; D002478:Cells, Cultured; D004176:Dipyridamole / Q000494:pharmacology*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis*; D008213:Lymphocyte Activation / Q000187:drug effects*; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D013936:Thymidine / Q000378:metabolism
D006684:HLA-DR Antigens; D015375:Receptors, Interleukin-2; D004176:Dipyridamole; D017493:Leukocyte Common Antigens; D013936:Thymidine